[Federal Register Volume 61, Number 223 (Monday, November 18, 1996)]
[Notices]
[Page 58694]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-29390]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 96N-0308]
Countrymark Cooperative, Inc.; Withdrawal of Approval of NADA
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of a new animal drug application (NADA) held by Countrymark
Cooperative, Inc. The NADA provides for the use of tylosin Type A
medicated articles to make Type C medicated feeds. Countrymark
Cooperative requested the withdrawal of approval of the NADA because
they are no longer making Type A medicated articles for use in Type C
medicated feeds. In a final rule published elsewhere in this issue of
the Federal Register, FDA is amending the regulations by removing those
entries which reflect approval of the NADA.
EFFECTIVE DATE: November 29, 1996.
FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for
Veterinary Medicine (HFV-216), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-594-1722.
SUPPLEMENTARY INFORMATION: Countrymark Cooperative, Inc., 950 North
Meridian St., Indianapolis, IN 46204-3909 (formerly the Indiana Farm
Bureau Cooperative Association, Inc., 120 East Market St.,
Indianapolis, IN 46204), has voluntarily requested withdrawal of
approval of NADA 125-226 that provides for use of tylosin Type A
medicated articles to make tylosin Type C medicated swine feeds.
Therefore, under authority delegated to the Commissioner of Food
and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary
Medicine (21 CFR 5.84), and in accordance with Sec. 514.115 Withdrawal
of approval of applications (21 CFR 514.115), notice is given that
approval of NADA 125-226, and all supplements and amendments thereto is
hereby withdrawn, effective November 29, 1996.
In a final rule published elsewhere in this issue of the Federal
Register, FDA is amending 21 CFR 510.600 and 558.625 to reflect
withdrawal of approval of this NADA.
Dated: October 18, 1996.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 96-29390 Filed 11-15-96; 8:45 am]
BILLING CODE 4160-01-F
